Notices. Notice
1,210 words·~6 min read·
/register/2017/07/18/2017-14999A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2015-D-3327] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; E6(R2) Good Clinical Practice; International Council for Harmonisation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget
(OMB)for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by August 17, 2017. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to *oira_submission@omb.eop.gov.* All comments should be identified with the OMB control number 0910-NEW and title “E6(R2) Good Clinical Practice; International Council for Harmonisation.” Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733; *PRAStaff@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Guidance on E6(R2) Good Clinical Practice; International Council for Harmonisation OMB Control Number 0910—NEW This information collection request supports Agency guidance entitled “E6(R2) Good Clinical Practice” (ICH E6(R2)), which was prepared under the auspices of the International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation. ICH E6(R2) amends the ICH guidance entitled “E6 Good Clinical Practice: Consolidated Guidance” (issued in April 1996) to encourage implementation of improved and more-efficient approaches to clinical trial design, conduct, oversight, recording, and reporting that are intended to increase clinical trial quality and efficiency while continuing to ensure human subject protection and reliability of trial results. Standards regarding electronic records and essential documents intended to increase clinical trial quality and efficiency have also been updated. The guidance includes additions to ICH E6(R1) that are identified as “ADDENDUM” and are marked with vertical lines on both sides of the text. In table 1, we estimate that approximately 1,457 sponsors of clinical trials of human drugs will develop approximately 1,457 quality management systems per year (as described in ICH E6(R2) in section 5.0, including sections 5.0.1 to 5.0.7). We further estimate that it will take sponsors approximately 60 hours to develop and implement each quality management system, totaling 87,420 hours annually. The estimated number of sponsors who will develop a quality management system, as described in ICH E6(R2), is based on the number of annual investigational new drug applications
(INDs)and new drug applications
(NDAs)submitted to the Center for Drug Evaluation and Research. The estimated number of hours it will take to develop a quality management system is based on FDA interactions with sponsors about activities that support drug development plans. In table 2, we estimate that approximately 1,457 sponsors of clinical trials of human drugs will describe the quality management approach implemented in a clinical trial and summarize important deviations from the predefined quality tolerance limits and remedial actions taken in the clinical study report (as described in section 5.0.7 of ICH E6(R2)). We further estimate that sponsors will submit approximately 4.6 responses per respondent and that it will take sponsors 3 hours to complete this reporting task, totaling 20,107 reporting hours annually. These estimates are based on FDA's past experiences with INDs and NDAs. In table 3, we estimate that approximately 218 sponsors of clinical trials of biological products will develop approximately 218 quality management systems per year (as described in ICH E6(R2) in section 5.0, including sections 5.0.1 to 5.0.7). We further estimate that it will take sponsors approximately 60 hours to develop and implement each quality management system, totaling 13,080 hours annually. The estimated number of sponsors who will develop a quality management system, as described in ICH E6(R2), is based on the number of annual INDs and biologics license application
(BLAs)submitted to the Center for Biologics Evaluation and Research. The estimated number of hours it will take to develop a quality management system is based on FDA interactions with sponsors about activities that support drug development plans. In table 4, we estimate that approximately 218 sponsors of clinical trials of biological products will describe the quality management approach implemented in a clinical trial and summarize important deviations from the predefined quality tolerance limits and remedial actions taken in a clinical study report (as described in section 5.0.7 of ICH E6(R2)). We further estimate that sponsors will submit approximately 3.69 responses per respondent and that it will take sponsors 3 hours to complete this reporting task, totaling 2,413 reporting hours annually. As described previously, these estimates are based on past experiences with INDs and BLAs submitted to the Agency. In the **Federal Register** of May 31, 2016 (81 FR 34345), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received on the proposed collection of information. FDA estimates the burden of this collection of information as follows: Table 1—Estimated Annual Recordkeeping Burden for Human Drugs 1 E6(R2) Good clinical practice; International Council for Harmonisation; guidance for industry Number of recordkeepers Number of records per recordkeeper Total annual records Average burden per recordkeeping Total hours Section 5.0—Quality Management (including sections 5.0.1 to 5.0.7)—Developing a Quality Management System 1,457 1 1,457 60 87,420 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Table 2—Estimated Annual Reporting Burden for Human Drugs 1 E6(R2) Good clinical practice; International Council for Harmonisation; guidance for industry Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours Section 5.0.7—Risk Reporting—Describing the Quality Management Approach Implemented in a Clinical Trial and Summarizing Important Deviations From the Predefined Quality Tolerance Limits and Remedial Actions Taken in the Clinical Study Report 1,457 4.6 6,702 3 20,107 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Table 3—Estimated Annual Recordkeeping Burden for Biologics 1 E6(R2) Good clinical practice; International Council for Harmonisation; guidance for industry Number of recordkeepers Number of records per recordkeeper Total annual records Average burden per recordkeeping Total hours Section 5.0—Quality Management (including 5.0.1 to 5.0.7)—Developing a Quality Management System 218 1 218 60 13,080 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Table 4—Estimated Annual Reporting Burden for Biologics 1 E6(R2) Good clinical practice; International Council for Harmonisation; guidance for industry Number of responses Number of responses per respondent Total annual responses Average burden per response Total hours Section 5.0.7—Risk Reporting—Describing the Quality Management Approach Implemented in a Clinical Trial and Summarizing Important Deviations From the Predefined Quality Tolerance Limits and Remedial Actions Taken in the Clinical Study Report 218 3.69 804 3 2,413 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Dated: July 12, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017-14999 Filed 7-17-17; 8:45 am]
Connectionstraces to 1
Traces to 1 document